ZYME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zymeworks Inc (ZYME) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's promising drug pipeline, strong analyst ratings, and financial flexibility through royalty-backed agreements outweigh the short-term negative price movements and recent financial losses.
The technical indicators are mixed but lean slightly bullish. The MACD is positive and contracting, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the RSI is neutral at 51.778. The stock is trading near a key pivot level of 23.874, with resistance at 25.321 and support at 22.426.
Promising clinical trial results for Zanidatamab in HER2-positive gastric cancer.
Analysts have raised price targets significantly, with a consensus Buy rating.
A $250 million royalty-backed financing agreement enhances financial flexibility and supports stock repurchase programs.
The company is shifting towards a royalty-focused strategy, which could stabilize long-term revenues.
Recent financial performance shows a significant Q4 revenue drop (91.9%) and a net loss of $41.2 million.
Short-term price trend is negative, with a -2.90% regular market change and -0.40% pre-market change.
No significant trading trends from hedge funds or insiders.
In Q3 2025, revenue increased by 72.59% YoY to $27.61 million, but net income dropped by 34.33% YoY to -$19.6 million. EPS also declined by 33.33% YoY to -0.26. Despite these losses, gross margin remained strong at 100%.
Analysts are highly optimistic, with multiple firms raising price targets recently. H.C. Wainwright raised its target to $46, Stifel to $47, and Truist initiated coverage with a $40 target. Analysts highlight the company's royalty-focused strategy and potential blockbuster drugs as key drivers for future growth.
